Endovascular placement of iodine-125 seed strand and self-expandable stent combined with transcatheter arterial chemoembolization for hepatocellular carcinoma with tumor thrombus in the main portal vein.
- Author:
Jian-jun LUO
1
;
Zhi-ping YAN
;
Jian-hua WANG
;
Qing-xin LIU
;
Xu-dong QU
;
Wen ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Carcinoma, Hepatocellular; pathology; therapy; Chemoembolization, Therapeutic; methods; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; therapeutic use; Liver Neoplasms; pathology; therapy; Male; Middle Aged; Neoplastic Cells, Circulating; Portal Vein; pathology; Stents; Survival Rate
- From: Chinese Journal of Oncology 2011;33(7):535-539
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the therapeutic effect of endovascular placement of iodine-125 seed strand and stent combined with transcatheter arterial chemoembolization (TACE) to treat hepatocellular carcinoma (HCC) with tumor thrombus in the main portal vein (MPVTT).
METHODSFifty patients with HCC complicated by MPVTT were enrolled into this study. There were 46 men and 4 women with a mean age of 53.9 years. TACE was performed after the iodine-125 seed strand and self-expandable stent placement in the obstructed segment of the main portal vein (MPV).
RESULTSTechnical success rate was 100% for placement of iodine-125 seed strand and stent in the target segment of MPV. No serious procedure-related complications occurred. The mean follow-up duration was 208.5 d. The mean and median survival time was 370.1 d and 223.0 d, respectively. The 90-, 180-, 360-day cumulative survival rates were 97.5%, 59.3%, and 38.4%, respectively. The mean and median patent time of stent was 524.2 d and 407.4 d, respectively. The 90-, 180-, 360-day cumulative patency rates of stent were 94.9%, 75.2%, and 64.5%, respectively.
CONCLUSIONEndovascular placement of iodine-125 seed strand and stent combined with TACE is an effective therapy for HCC with tumor thrombus in the main portal vein.
